APPEN
7.3.2019 17:02:08 CET | Business Wire | Press release
Appen Limited today announced the achievement of ISO/IEC 27001:2013 accreditation for its facility in Cavite, Philippines to meet the rapidly growing demand for human-annotated datasets used by companies worldwide to train machine learning and artificial intelligence (AI) applications.
The facility was established to ensure commercial confidentiality and better support privacy management. Globally recognized, the ISO/IEC 27001:2013 standard defines the requirements for an Information Security Management System (ISMS), and a process-based approach for establishing, implementing, operating, monitoring, maintaining and improving the ISMS.
ISO/IEC 27001:2013 accreditation underpins Appen’s ability to work on datasets for clients that contain personally identifiable information – data that could potentially identify a specific individual – as well as other sensitive material, such as data related to new product development.
“Appen’s facility in the Philippines gives clients enhanced options to scale their AI programs with the assurance that their sensitive data and projects will remain secure,” said Mark Brayan, Appen’s chief executive officer. “It’s the perfect complement to our high-security facility in the U.K., and is an important part of our suite of secure at-home and in-facility solutions.”
Appen works with the world’s leading technology companies, as well as firms across all industries to provide high-quality data for their machine learning programs. Appen’s suite of secure solutions includes secure facilities as well as secure remote worker options designed to scale customers’ machine learning programs while maintaining data privacy. Use case examples range from voice recognition in smart speakers to geospatial analysis in self-driving cars, to intelligent search and online advertising results.
Industry analysts estimate the data collection and annotation market will be worth up to $19 billion – approximately 10% of the overall AI market – by 2025. The explosive growth is attributed to the need for high volumes of annotated data that are required to improve AI algorithm accuracy. Today, approximately one-third of AI applications require frequent or monthly data updates, and one-quarter of those need weekly updates, according to McKinsey Global Institute.
Datasets created by Appen include image, text, audio, video and relevance data, as well as speech and natural language data from over 130 countries and more than 180 languages and dialects.
The announcement today follows Appen’s recent reporting of record results of AU$364.3 million in 2018, representing 119% growth year-over-year.
During the company shareholder call last week, Brayan outlined Appen’s 2019 growth initiatives that include increasing technology development to improve the productivity of its global crowd of over 1 million skilled contractors who develop the AI training datasets in conjunction with Appen’s Client Services team. In addition to expanding Appen’s secure solutions, the company also plans to increase its full-time staff and investments in China, the largest AI market outside of the U.S.
Founded in 1996, Appen has office locations worldwide including Seattle, San Francisco, Detroit, and Beijing in addition to the Philippines, U.K. and its headquarters in Sydney.
About Appen
Appen is a global leader in the development of high-quality, human-annotated datasets for machine learning and artificial intelligence. Appen brings over 20 years of experience capturing and enriching a wide variety of data types including speech, text, image, and video. With deep expertise in more than 180 languages and access to a global crowd of over 1 million skilled contractors, Appen partners with technology, automotive and e-commerce companies — as well as governments worldwide — to help them develop, enhance and use products that rely on natural languages and machine learning.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005137/en/
Contact:
Jodie Ruby VP of Marketing jruby@appen.com 425-442-8014
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
